Xconomy: Dendreon has only itself to blame for Provenge fiasco

Xconomy's Luke Timmerman takes Dendreon to task for its acknowledged blunder marketing Provenge. Chiding the biotech for overreaching on price, failing to get its marketing ducks in a row ahead of an approval and fumbling its outreach to physicians, Timmerman adds that Dendreon's ($DNDN) failure is limited to a single company, with more experienced players like Vertex (Incivek) and Bristol-Myers Squibb (Yervoy) finding success with their new drugs. Of course, their success also begs the question whether Dendreon had fully explained all the reasons for Provenge's sudden disappointment. And today, on another bad day on Wall Street, Dendreon's battered shared slid another 11 percent. Column

Suggested Articles

Maryland researchers discovered a type of stem cell in hair follicles that can rebuild the myelin that breaks down in brain diseases like multiple sclerosis.

Three weeks after filing luspatercept for FDA approval, Celgene has submitted the anemia drug for consideration by the European Medicines Agency.

The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.